Skip to main content
Clinical Trials/NCT05894759
NCT05894759
Recruiting
Not Applicable

Psychodermatological Approaches of Psoriasis

Grigore T. Popa University of Medicine and Pharmacy1 site in 1 country105 target enrollmentJune 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Psoriasis
Sponsor
Grigore T. Popa University of Medicine and Pharmacy
Enrollment
105
Locations
1
Primary Endpoint
Psychological stress
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Two mind-relaxing techniques will be applied to psoriasis patients with an elevated psychological stress profile at baseline

Registry
clinicaltrials.gov
Start Date
June 2023
End Date
August 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Grigore T. Popa University of Medicine and Pharmacy
Responsible Party
Principal Investigator
Principal Investigator

Bogdan-Marian Tarcau

Principal investigator

Grigore T. Popa University of Medicine and Pharmacy

Eligibility Criteria

Inclusion Criteria

  • clinical diagnosis of psoriasis
  • adequate psychological stress profile
  • access to a personal computer/ laptop/ smartphone with internet connection
  • agreement to the informed consent form

Exclusion Criteria

  • other dermatological conditions which impair the life quality
  • psychological disorders under psychiatric treatment
  • hearing impairment
  • other on-going medical studies
  • pregnancy
  • aliteracy

Outcomes

Primary Outcomes

Psychological stress

Time Frame: 6 months

A visual analog scale will be used at baseline, 1 month and 6 months. Analog scale minimum value = 0 (no stress) Analog scale maximum value = 10 (maximum stress)

General Anxiety Disorder-7

Time Frame: 6 months

General Anxiety Disorder-7 questionnaire will be applied at baseline, 1 month and 6 months. General anxiety disorded-7 minimum score = 0 (no anxiety) General anxiety disorded-7 maximum score = 21 (maximum anxiety)

Patient Health Questionnaire-9

Time Frame: 6 months

Patient Health Questionnaire-9 will be applied at baseline, 1 month and 6 months. Patient Health Questionnaire-9 minimum score = 0 (no depression) Patient Health Questionnaire-9 maximum score = 27 (maximum depression)

Dermatological Life Quality Index

Time Frame: 6 months

Dermatological Life Quality Index Score will be calculated at baseline, 1 month and 6 months. Dermatological Life Quality Index minimum score = 0 (no impairment of life quality) Dermatological Life Quality Index maximum score = 30 (maximum impairment of life quality)

Secondary Outcomes

  • Psoriasis Area and Severity Index(6 months)
  • The Revised Illness Perception Questionnaire(6 months)
  • Dermatological treatment compliance(6 months)
  • Self Administered Psoriasis Area and Severity Index(6 months)

Study Sites (1)

Loading locations...

Similar Trials